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Abstract Classical physiology teaches that vagal post-
ganglionic nerves modulate the heart via acetylcholine
acting at muscarinic receptors, whilst it is accepted that
vagus nerve stimulation (VNS) slows heart rate, atrioven-
tricular conduction and decreases atrial contraction; there is
continued controversy as to whether the vagus has any
significant direct effect on ventricular performance.
Despite this, there is a significant body of evidence from
experimental and clinical studies, demonstrating that the
vagus nerve has an anti-arrhythmic action, protecting
against induced and spontaneously occurring ventricular
arrhythmias. Over 100 years ago Einbrodt first demon-
strated that direct cervical VNS significantly increased the
threshold for experimentally induced ventricular fibrilla-
tion. A large body of evidence has subsequently been
collected supporting the existence of an anti-arrhythmic
effect of the vagus on the ventricle. The development of
prognostic indicators of heart rate variability and barore-
ceptor reflex sensitivity—measures of parasympathetic
tone and reflex activation respectively—and the more
recent interest in chronic VNS therapy are a direct conse-
quence of the earlier experimental studies. Despite this,
mechanisms underlying the anti-arrhythmic actions of the
vagus nerve have not been fully characterised and are not
well understood. This review summarises historical and
recently published data to highlight the importance of this
powerful endogenous protective phenomenon.
Keywords Vagus nerve stimulation  Heart failure 
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Sudden cardiac death and the autonomic nervous
system
Sudden cardiac death (SCD) resulting from malignant
ventricular arrhythmias including ventricular tachycardia
(VT) and ventricular fibrillation (VF) represents a signifi-
cant unsolved clinical problem with an annual death toll of
over 325 000 people in the USA (Heart Rhythm Founda-
tion [1]) and around 70,000 in the UK (NICE [2]). The
search for prophylactic treatments for SCD remains fun-
damental and is particularly important in heart failure (HF)
which is associated with a significantly increased arrhyth-
mic mortality. A distinctive hallmark of HF is that of
autonomic disturbance, that is, increased sympathetic
activity and decreased parasympathetic tone. Abnormal
autonomic function is been described in all aspects of
regulation including alterations to afferent nerve activity,
central processing, ganglionic and efferent innervation and
alterations to the heart itself. Alterations in autonomic
activity arise early in the pathogenesis of HF and appear to
precede other stereotypical changes. In a canine tachycar-
dia-induced HF model, vagal tone decreased 3 days after
the development of cardiac dysfunction, often preceding
the enhancement of sympathetic activity [3, 4]. Activity of
the arterial chemoreceptors [5] and cardiac sympathetic
afferent fibres [6] are increased, in part, to drive the
increase in sympathetic outflow. Enhanced sympathetic
activation occurs before the development of symptoms in
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patients with left ventricular (LV) dysfunction, and reduced
parasympathetic drive is present early in patients with
symptomatic HF resulting from even mild LV impairment
[7].
There is strong evidence that the relationship between
impaired neurocardiological control and increased mortal-
ity is the result of an increased vulnerability to lethal
ventricular arrhythmias [8]. Whilst the clinical and prog-
nostic significance of sympathetic over-activation is well
established [9] and forms the rationale for b-blockers as
standard HF therapy, parasympathetic regulation and its
modulation has received much less attention. There is,
however, important evidence illustrating that the vagus
nerve has an antiarrhythmic action in the ventricle. The
mechanisms by which the autonomic nervous system,
especially its parasympathetic branch, influences ventric-
ular arrhythmias are poorly understood and SCD remains a
significant clinical problem. Advances in our ability to treat
HF have allowed for significant improvements in patient
survival; however, a significant proportion of patients still
die suddenly as a result of malignant arrhythmias. Whilst
milder forms of heart failure (NYHAs II and III) are
associated with lower mortality compared to NYHA IV,
the proportion of overall mortality attributable to lethal
ventricular arrhythmias is higher [10]. Although there is no
direct data exploring this notion, it is tempting to postulate
that measures which improve HF status, whilst reducing
overall mortality (with pump failure death as main con-
tributor), paradoxically convert patients into a ‘more
arrhythmogenic’ HF phenotype. To achieve further
improvements in patient survival, new therapeutic strate-
gies are required to address this. The vagus nerve could
provide a powerful endogenous anti-arrhythmic means to
achieve such an end. This review aims to discuss historical
and recent developments in our understanding of the anti-
arrhythmic influence of the vagus on the ventricle focus-
sing on the mechanisms of its protective effect. The use of
vagus nerve stimulation (VNS) for the prevention of
malignant ventricular arrhythmias in HF will be dis-
cussed—relating phenotypical changes associated with the
syndrome with data on its mechanisms of action.
Parasympathetic tone and patient prognosis
There is a strong correlation between survival and ‘mark-
ers’ of parasympathetic tone in patients with HF irrespec-
tive of b-blocker therapy [11–13] or following myocardial
infarction (MI) [14]. Due to the invasive nature of the
direct measurement of vagal activity, studies rely on indi-
rect measurements of sinus node behaviour in the form of
heart rate variability (HRV) and baroreceptor reflex sen-
sitivity (BRS). HRV is a measure of the variability of time
interval between heart beats (RR interval) and reflects the
activity of sympathetic and parasympathetic branches.
Several measures of HRV including the standard deviation
of the RR interval (SDNN) [15] and the low-frequency
component on power spectral analysis [16] are independent
risk markers. BRS measures changes in heart rate in
response to pressor doses of phenylephrine and/or vasodi-
latory sodium nitroprusside (SNP) reflecting a reflex
pathway primarily involving the parasympathetic nervous
system [17, 18]. BRS is calculated from plots of heart rate
or RR interval as a function of the change in blood pres-
sure, the slope of the relationship provides the BRS. The
predictive power of indirect measures of parasympathetic
activity was first demonstrated in animal studies. A
reduction in BRS correlates with an increased occurrence
of SCD in animals with healed MI subjected to exercise
and acute coronary artery occlusion (CAO) [18, 19]. Larger
studies subsequently revealed BRS to be a strong predic-
tive marker both before MI and after MI, where a depressed
BRS predicts a higher risk [20]. Studies of single cardiac
vagal fibre activity reveal an increase in vagal activity
immediately following CAO occurred in animals destined
to survive and that depressed vagally activity in response to
changes in blood pressure predicted an increased risk of
SCD post-MI [21].
Several small- and large-scale clinical trials have dem-
onstrated the predictive value of BRS and HRV in patient
populations. An early prospective clinical study reported
that a low BRS was significantly associated with greater
all-cause mortality [17], and a subsequent follow-up trial
found a strong association between BRS and the occurrence
of malignant arrhythmic events but not with all-cause mor-
tality [22]. Several time domain measures of HRV are also
reported to be powerful predictor of all-cause mortality
following MI [15, 23–25]. Low-frequency (typically \
0.04 Hz) power from spectral analysis of RR intervals
reflects vagal tone, and its reduction correlates with all-cause
mortality and arrhythmic death independent of other factors,
for example, left ventricular ejection fraction [16]. The
prognostic value of BRS and HRV has been confirmed in
large-scale (500–1,000 ? patients) randomised clinical trials
conducted in patients post-MI (ATRAMI [14]) and in
patients with chronic HF (UK-HEART [13]).
The parasympathetic nervous system and ventricular
arrhythmias
The dogma of physiology teaching states that vagal post-
ganglionic nerves modulate the heart through acetylcho-
line (ACh) acting on muscarinic receptors (mAChRs) to
slow heart rate, increase atrioventricular conduction and
inhibit atrial force, with little influence on ventricular
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performance. The latter reflects historical reports that
ventricular parasympathetic (cholinergic) innervation was
sparse. This view is, however, outdated because modern
histological techniques reveal a dense and intricate network
of ACh containing nerves running over the epi- and endo-
cardial surfaces of left and right ventricles and a wide-
spread distribution of mAChRs throughout the ventricle
[26]. More importantly, it is worth reminding readers that
the vagal-cholinergic pathway is capable of inhibiting the
strong inotropic response to adrenergic activation [27] and
as such has a clear functional role. Dense parasympathetic
innervation is demonstrated in all species studied including
the mouse [28, 29], guinea pig [30], cat [31], dog [32], pig
[33], sheep [34] and human ventricle [35, 36] (see Fig. 1).
Parasympathetic innervation and receptors
The somata of the parasympathetic efferent pre-ganglionic
neurones arise chiefly from the ventral lateral region of the
nucleus ambiguous, and a smaller proportion from the
dorsal motor nucleus and intermediate zone between these
sites [37]. Pre-ganglionic fibres are carried within the Xth
cranial nerve, that is, the vagi and converge at several atrial
and ventricular ganglionated plexuses which regulate car-
diac function through post-ganglionic projections post-
ganglionic in the atrial and ventricular tissues. Significant
laterality is noted in the effects of the two vagi with the
right vagus, exerting a greater influence on the sinoatrial
node than the left vagus [39, 40] with a greater influence of
the left vagus on atrioventricular conduction in the rabbit
[38], although significant overlap exists [41]. The existence
of laterality is clinically important for the application of
VNS where excessive bradycardia should be avoided.
There is a complex network of neuronal subtypes within
the ganglionated plexuses which can modulate the heart on
a beat-by-beat basis that can act independent of peripheral
input [40]. The role of this heart brain, reviewed by
Armour [41], is an emerging and fascinating area of
research with potential implications in the autonomic
modulation of both atrial and ventricular arrhythmias. This
is highlighted by evidence that neurochemical stimulation
of decentralised intrinsic cardiac neurones can generate
atrial and ventricular arrhythmias [42] and that reduced
vagal tone in HF may be directly attributable to changes in
ganglionic function [43].
Post-ganglionic vagal fibres are primarily cholinergic in
nature releasing ACh which act on mAChRs. Five distinct
mAChRs subtypes (M1–M5) have been described, and 3
subtypes are found within the heart (M2, M3, and M4) [44–
46]. The most abundant mAChR is the Gi-protein-coupled
M2 receptor and is found on cardiomyocytes [44] and
within intracardiac ganglia [47]. Evidence from receptor
knockout mice suggests that the M2 receptor subtype is
predominantly responsible for regulating cardiac function
[45] through a Gi-protein mediated direct action on ACh-
dependent ion channels such as IKAch and indirect effects
on inhibition of adenylate cyclase activity that reduces
Fig. 1 Parasympathetic innervation of the mammalian ventricles. A
composite of images demonstrating extensive parasympathetic inner-
vation of the ventricles of the pig and dog. a Acetylthicholine
precipitation demonstrating the gross morphology of parasympathetic
fibres innervating the epi- and endocardial regions of the porcine
ventricles. b Histochemical staining of acetylcholinesterase contain-
ing nerve fibres in the 1-month-old canine heart. Reproduced with
permission from Ulphani et al. [33] and Taggart et al. [150]
respectively
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intracellular cAMP. cAMP is known to stimulate the non-
selective cationic current (If) which drives spontaneous
depolarisation of pacemaker tissues such as the sinoatrial
and atrioventricular nodes and purkinje fibres. The acti-
vation of the IKACh results in membrane hyperpolarisation,
increasing the cells threshold for firing which contribute to
heart rate reduction. M3 and M4 ACh receptors are [46]
preferentially linked with Gq-proteins. The role of the M3
receptor in regulating cardiac function, especially electro-
physiology, is discussed later. In addition to ACh, several
peptides are co-localised within cholinergic neurones. The
most common is vasoactive intestinal peptide (VIP) which
is considered to be positively inotropic by increasing
adenylate cyclise activity, although this is contentious [48].
It is therefore possible that VIP interacts with ACh at the
post-junctional level, opposing the inhibitory actions of
ACh on intracellular cAMP accumulation.
Vagal modulation of arrhythmia susceptibility
Table 1 presents a summary of studies investigating the
effects of VNS on the occurrence of ventricular arrhyth-
mias under a number of conditions. This table aims to
summarise the methodological approaches used in each
study and to present the results of each study in a con-
densed but comprehensive format.
Historical perspective
The first report that VNS reduced the susceptibility of the
ventricle to experimental arrhythmia was presented by
Einbrodt in 1859 [49], who demonstrated that VF was
harder to induce in the dog during stimulation of the vagus.
The anti-arrhythmic action of VNS was later reproduced by
Scherlag et al. [50] who showed that VNS interrupted the
spontaneous occurrence of VT during CAO. Studies by
Goldstein et al. [51], Myers et al. [52] and several others
[53–56] in the 1970s confirmed the anti-arrhythmic action
of VNS. Several studies provide evidence that VNS is
protective against experimental-induced VF using undis-
eased hearts [54–56]. Kent et al. [56] demonstrated a VNS-
dependent increase in the current required to induce VF,
using a train of electrical pulses applied during the
refractory period, that is, the ventricular fibrillation
threshold (VFT), in the anaesthetised dog. Yoon et al. [55]
similarly demonstrated a significant increase in VFT during
VNS which was not maintained in the presence of the non-
selective b-adrenergic antagonist propranolol. Similarly, a
study by Kolman et al. [54], in which the left stellate
ganglion was crushed, demonstrated no anti-arrhythmic
effect in control conditions but found significant protection
when VNS was applied after stimulation of sympathetic
nerves suggesting significant sympathetic–parasympathetic
interactions in the anti-arrhythmic action of VNS, which
are discussed in later.
A number of studies have shown that VNS prevents
arrhythmias as a result of CAO. Myers et al. [52] investi-
gated the effects of low- and high-frequency VNS on
spontaneous VF during acute CAO. Vagal stimulation was
associated with an intensity-dependent reduction in VF
occurrence that was coupled with higher survival rates.
These data are supported by Kent et al. [56]. In the con-
verse experiment, Corr and Gillis [57] found that bilateral
vagotomy and atropine perfusion increased CAO-induced
mortality, suggesting that intrinsic vagal activity was pro-
tective. In contrast, Yoon et al. [55] reported no effect of
vagal stimulation on VFT in the ischaemic dog heart
despite a pronounced response in non-ischaemic controls.
A study conducted by Zuanetti et al. [58] demonstrated
effects of bilateral vagotomy and of VNS on the occurrence
of malignant ventricular arrhythmias (VF or fast sustained
VT) following reperfusion of the ischaemic feline myo-
cardium—a reduction in the incidence of both VF and fast
sustained VT occurred during VNS whilst bilateral vagot-
omy resulted in a 55 % reduction in arrhythmia occurrence
when compared to unoperated controls.
Studies in a canine model of SCD
An elegant canine model of SCD developed by Peter
Schwartz and colleagues has been used extensively to
study the protective effect of the vagus in conscious ani-
mals aimed at circumventing the confounding influence
of anaesthetics [19, 20, 59, 60]. Animals are subjected to
ligation of the left anterior descending coronary artery,
instrumented for future studies and subsequently allowed to
recover for 1 month. Surviving animals go onto a treadmill
exercise test with progressively increasing workload toge-
ther with CAO of the left circumflex artery from the start of
the last minute of the exercise regime for a period of 2 min
resulting in the reproducible occurrence of VF in 50–60 %
of animals [20, 59]. An ischaemia-induced reduction in
heart rate in those dogs which survived suggests that active
vagal reflexes protect from malignant ventricular arrhyth-
mias. De Ferrari et al. [19] later studied vagal tone in these
animals. The authors found that muscarinic blockade with
atropine promoted premature ventricular contractions, VT
and VF in animals with no arrhythmia during control. The
activation of strong vagal reflexes (i.e. HR reduction fol-
lowing CAO) was shown to be important for survival in
25 % of animals studied and was significantly correlated
with measures of BRS. Vanoli et al. [60] studied the effects
of direct VNS on the occurrence of SCD in dogs that
survived MI. Right VNS, applied before and throughout
CAO, reduced the occurrence of VF from 92 % in control
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to 10 % during VNS. These data provide strong supportive
evidence of the important anti-arrhythmic protection of the
vagus nerve on the ventricle.
Studies in the isolated innervated rabbit heart
The onset of VF is believed to be associated with the
break-up of spiral waves or rotors into multiple wavelets
and oscillations in electrical activity [61]. One mechanism
considered key in the development of these oscillations is
electrical restitution. Electrical restitution is the relation-
ship between action potential duration (APD) preceding
diastolic interval (DI). APD is relatively long at slow heart
rates (long DI) but shortens with high heart rates or an
ectopic beat (short DI). The magnitude of APD shortening
with changes in DI characterises the dynamics of restitu-
tion which can be described by the maximum slope during
restitution curve (plot of APD vs. DI). The ‘restitution
hypothesis’ proposes that the slope of the APD restitution
curve is related to the susceptibility to arrhythmia initia-
tion. Typically oscillations are facilitated when the slope
of the APD restitution curve is[1 [62]. In situations with a
steep restitution curve, a small change in DI leads to a
large change in APD and hence dynamic instability and is
supported from data from mathematical [63, 64] and bio-
logical studies [62, 65] relating to VF vulnerability [66,
67]. In addition, there is supportive evidence from drugs
that reduce restitution slope also prevent VF [65]. Using
the isolated innervated rabbit heart preparation, we
investigated the effects of VNS on electrical restitution and
ventricular fibrillation susceptibility [68]. VNS caused a
flattening of the electrical restitution slope, an increase in
the current required to induce ventricular fibrillation
(increased VFT) alongside a prolongation of MAPD and
ERP (see Fig. 2). VFT was inversely correlated with the
slope of the electrical restitution curve, in keeping with the
restitution hypothesis that predicts an increase in arrhyth-
mia susceptibility as the slope increases. The anti-fibril-
latory effect of the vagus nerve occurs in the absence of
any background sympathetic activity [38], suggesting a
direct anti-arrhythmic effect which is separate from the
indirect action concerning antagonism of adrenergic
effects (accentuated antagonism), which is evident from
single cells studies using pharmacology investigating the
effects on individual ionic currents from heart failure
preparations [69].
Spontaneous versus induced arrhythmia
The use of ‘spontaneous’ and induced methods of
arrhythmia occurrence is a contentious issue that warrants
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methodologies to generate arrhythmias which rely on
spontaneous arrhythmia generation. Studies utilising CAO
often use quantitative measures of arrhythmic events, that
is, number of premature ventricular contractions (PVCs),
VT and VF or the time course of these events. A disad-
vantage of this approach is the stochastic nature of
arrhythmic event occurrence. The development of the
canine model of SCD addressed many of the issues of
reproducibility [59]. However, this method is rather time-
consuming, expensive, technically difficult and is highly
dependent upon multiple factors, that is, ischaemia and
adrenergic activation. Whilst this model could be viewed
as physiologically relevant, the assessment and investiga-
tion of the direct effects of VNS are not possible. VFT
provides a quantifiable and robust measure of arrhythmia
susceptibility, allowing that the examination of how
physiological, pathophysiological and pharmacological
factors can affect electrical stability in addition to effects
from nerve stimulation. VFT is widely used for the study of
arrhythmia susceptibility and has been shown to predict the
increased and decreased susceptibility of the ventricle to
arrhythmias in a range of situations [56, 66, 70]. Some
investigators are concerned that VFT does not predict the
anti-arrhythmic actions of certain drugs and fails to predict
the occurrence of spontaneous arrhythmias [71]. However,
Harumi et al. [72] have demonstrated that anti-arrhythmic
drugs can be classified depending upon their effects on
VFT, ventricular refractoriness and electrical restitution
properties, indicative of the multiple mechanisms of action
of many of these drugs. Despite these limitations, VFT
appears to be a reliable indicator for the effects of the
autonomic nervous system on ventricular arrhythmias [55,
56].
Vagus nerve-mediated protection from malignant
arrhythmias in heart failure
Data on the use of vagal stimulation in the treatment for
arrhythmia secondary to HF are somewhat limited despite
Fig. 2 Autonomic modulation of electrical restitution and ventricular
fibrillation threshold. The effects of bilateral sympathetic (SS) and
parasympathetic (VS) nerve stimulation on the slope of the electrical
restitution curve, effective refractory period (ERP) and ventricular
fibrillation threshold (VFT) of the isolated innervated rabbit heart.
a and b Data from a single experiment demonstrating the effect of SS
and VS on the electrical restitution curve. c and d Mean data on the
effects of SS and VS on the restitution slope, ERP and VFT. BL
baseline. *P \ 0.05; comparison to baseline. Reproduced with
permission from Ng et al. [68]
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the fact that ventricular arrhythmias are responsible for a
large proportion of SCDs and that arrhythmic disturbance,
that is, ectopic beats or runs of non-sustained ventricular
tachycardia, occurs in 50–80 % of all HF patients [73, 74].
The effects of chronic vagal stimulation on arrhythmias
occurrence in conscious rats with MI-induced HF were
investigated by Zheng et al. [75]. Right cervical VNS
conducted 3–5 months post-MI for a period of 7 days
prevented the characteristic occurrence of premature ven-
tricular and supraventricular contractions. Sabbah [76]
reported on the effects of chronic VNS in dogs with mic-
roembolism-induced HF. In these studies, VNS was
applied using a negative-feedback loop to maintain heart
rate at a level 10 % below baseline for a 3-month period.
While the main focus of this study was to look at the effect
of VNS on haemodynamics and ventricular remodelling,
the effect of VNS on gap junction protein expression was
documented. HF causes translocation of the gap junction
protein connexin away from the intercalated discs which
regulate cell-to-cell excitability, allowing the passage of
small ions between adjacent cardiomyocytes. Disruptions
to this cell-to-cell coupling play an important role in
arrhythmogenesis and underpin conduction through the
myocardium. Reduced expression of connexin-43, the
primary form expressed in the ventricular myocardium,
slows ventricular conduction and increases the dispersion
of transmural APD which is linked to the increased inci-
dence of tachyarrhythmias and SCD [77, 78]. VNS therapy
reverses the reduction in connexin-43 mRNA and protein
expression associated with HF [76], providing strong sup-
portive, yet indirect, evidence that VNS may have anti-
arrhythmogenic properties in the failing heart. The effects
of VNS can be mimicked by the use of pharmacological
agents. Pyridostigmine, a cholinesterase inhibitor, decrea-
ses the rate of ACh degradation at the post-ganglionic
synapse and prevents the occurrence of single ventricular
ectopic beats in patients with HF NYHA class I to III and
an ejection fraction of\45 %, although no effect was noted
on paired ectopic beats or on the occurrence of periods of
ventricular tachycardia [79]. The suppression of cardiac
arrhythmias in congestive HF by clonidine [80], a centrally
acting a2 adrenoceptor agonist which acts to suppress
sympathetic nervous activity, demonstrates how VNS
could be used to antagonise the pro-arrhythmic influence of
the sympathetic nervous system. Despite limited data on
the effects of VNS on arrhythmia susceptibility, there is
strong evidence that VNS improves autonomic balance in
HF [81, 82], reducing sympathetic hyperactivity and
increasing vagal tone, highlighting its potential as an anti-
arrhythmic therapy.
In addition to its anti-arrhythmic properties, chronic
VNS has been shown to reverse the contractile dysfunction
and adverse remodelling associated with experimental HF
[81–84] and appears to be beneficial even when applied at
subthreshold intensities insufficient to cause changes in HR
[85]. The clinical application of chronic vagal therapy is
recently described by De Ferrari and Schwartz [85] and
will not be discussed in detail here. It is worthy to note that
the profound and beneficial effects of the vagus nerve on
the cardiovascular system have prompted a number of
clinical trials (i.e. INOVATE-HF and NECTAR-HF),
examining the application of chronic VNS in the treatment
for HF [85]. There is clearly a need for further study on the
potential benefit of VNS in the prevention of arrhythmias
in HF, especially given that arrhythmia-related deaths
remain a significant clinical burden in spite of advances in
treatment [10]. Robust clinical trials will be required to
truly assess the role of VNS in this regard, but it is possible
to speculate how VNS may be beneficial in the treatment
for HF on the basis of what we know about the ‘disease’
process and its phenotypical characteristics.
Mechanisms of the anti-arrhythmic effect of the vagus
nerve
Vagal stimulation modulates ventricular arrhythmias by a
number of direct and indirect actions including activation
of muscarinic receptors, antagonism of sympathetic
actions, heart rate reduction, prolonged APD and reduced
APD dispersion, effects on restitution/refractoriness, and
possibly via nitric oxide (NO). Several theories describe
how alterations in cardiac electrophysiological parameters
may influence the generation and propagation of ventric-
ular arrhythmias. Table 2 summarises some of the tentative
mechanisms underlying arrhythmogenesis and how the
vagus nerve may act via these factors.
Accentuated antagonism
Interaction between the sympathetic and parasympathetic
branches of the autonomic nervous system is complex.
Competitive antagonism between autonomic divisions
provides an important site of regulation. Samaan [86] first
illustrated that vagal stimulation attenuated the chrono-
tropic enhancement associated with sympathetic nerve
stimulation (SNS), by demonstrating that the actual change
in HR with concomitant VNS and SNS was different to the
algebraic sum of the heart rate changes during individual
stimulation of each branch. This was later termed ‘accen-
tuated antagonism’ by Levi and Zieske in [87]. These data
demonstrate that the vagus has a powerful antagonistic
effect on the chronotropic effect of SNS which is con-
firmed by others [57]. A similar antagonistic action exists
in the control of ventricular performance, intracellular
calcium handling and cardiac electrophysiology [87–90].
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Interaction between the sympathetic and vagal systems
occurs via pre- and/or post-junctional mechanisms. ACh
binds to mAChRs, on the pre-synaptic sympathetic nerve
terminals (M3) and M2 receptors on cardiomyocytes to
inhibit noradrenaline (NA) release and/or accumulation of
intracellular cAMP, respectively [89, 91–94]. With respect
to arrhythmogenesis, Kolman et al. [54] reported that the
beneficial effects of VNS on ventricular arrhythmia vul-
nerability were entirely attributed to parasympathetic–
sympathetic interaction as the protective effect of VNS was
abolished by propranolol. Similarly, the anti-arrhythmic
effect of VNS in undiseased hearts is abolished by treat-
ment with propranolol [81]. Several investigators have
shown a reduction in the anti-arrhythmic effect of VNS
following treatment with atropine, supporting the role of
muscarinic receptor activation in these studies [77, 81].
It should also be noted that the sympathetic nervous
system can regulate the vagal release of ACh and exerts
antagonistic effects at the myocyte level through the
actions of NA and co-released neuropeptide Y (NPY)
[95–103]. How these signalling pathways are involved in
arrhythmogenesis remains to be elucidated.
The role of accentuated antagonism in regulating sym-
pathetic outflow to the heart is nothing new; however, it is
particularly relevant to the pathogenesis of HF. HF repre-
sents a deleterious spiral of events in which cardiac function
declines, necessitating an increase in cardiac output which
is mediated through and increase in sympathetic activity.
The resulting increase in demand, on an already compro-
mised system, results in further deterioration and a greater
requirement for increased sympathetic tone to support
cardiac output. By our understanding of sympathetic–
parasympathetic interaction, if there is an increase in sym-
pathetic activity, there tends to be a reciprocal decrease in
parasympathetic tone, as evidenced in studies using HRV
and BRS [13, 14]. The beneficial effects of b-blockade
Table 2 Tentative mechanisms by which the vagus nerve can exert anti-arrhythmic action on the ventricle
Electrophysiological
parameter
Relationship to arrhythmias Modulation by the vagus nerve
Electrical restitution : Slope of the electrical restitution curve (APD vs. DI)
Dynamic Instability at short DI
: Arrhythmic risk
: Spatial dispersion of restitution
: Arrhythmic risk








Some evidence of uniform prolongation
; Arrhythmic risk
APD dispersion : Symp drive
Innervation BASE [ APEX
: APD dispersion
: Arrhythmic risk
GJ remodelling in ischaemia and HF
: Transmural APD dispersion
: Arrhythmic risk
VNS ; Symp drive
; APD Dispersion
Direct VNS : APD : ERP and ;VFT
Rate-dependent and independent effects
VNS ; GJ remodelling
Direct M3 MAChR modulation of GJ
Conduction Gap junction remodelling in ischaemia and HF
Slower conduction
: Arrhythmic risk
VNS ; GJ remodelling




: Ca2? load in SR
: DADs and spontaneous contractions
: Arrhythmic risk
VNS ; NA release and cAMP accumulation
; SR Ca2? load
No evidence of direct effect on Ca2? handling
in unstimulated ventricular tissue
Premature ventricular
contractions




VNS ; premature ventricular contractions in
animals with chronic HF
; Arrhythmic risk
APD action potential duration, Ca2? calcium, DADs delayed after depolarisations, DI diastolic interval, ERP effective refractory period, HF
heart failure, MAChR muscarinic acetylcholine receptor, NA noradrenaline, NO nitric oxide, SNS sympathetic nerve stimulation, Symp sym-
pathetic, VFT ventricular fibrillation threshold, VNS vagus nerve stimulation
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therapies in the treatment for HF highlight how antagonis-
ing the action of sympathetic nervous system puts a ‘brake’
on this vicious cycle which improves the quality of life and
extends life expectantly [10]. b-Blockade not only decrea-
ses energetic demand in the heart, but, in theory, could
reduce the sympathetic antagonism of the parasympathetic
nervous system. There is, therefore, an inherent difficulty in
attributing beneficial effects of b-blockade to a single
mechanism. In reference to arrhythmias, the benefits appear
to be mediated by (1) a reduction in the direct actions of the
sympathetic nervous system on the ventricular myocar-
dium, (2) an enhancement of parasympathetic outflow or (3)
a combination of these two. As discussed below there are
several mechanisms whereby the parasympathetic nervous
system directly influences ventricular arrhythmia suscepti-
bility. The use of VNS for the treatment for HF may
be viewed as a complementary approach to b-blockade,
whereby vagal tone is increased by direct electrical stimu-
lation. The benefit of VNS on protecting against ventricular
arrhythmias may occur through (1) a direct action on of the
vagus on the ventricle, (2) antagonism of the actions of the
SNS or (3) a combination of these factors. The former is
supported by our studies in the isolated innervated rabbit
heart, demonstrating a significant anti-arrhythmic action of
VNS [68] in the absence of underlying sympathetic nervous
activity [38].
Direct muscarinic receptor dependent effects—the M3
receptor
Several studies have demonstrated that the beneficial effect
of the vagus nerve on the occurrence of VF is related to
muscarinic receptor activation. Perfusion of atropine, a
non-selective muscarinic receptor antagonist, increased the
occurrence of CAO-induced VF in several studies [56],
including studies conducted in the canine model of SCD
[19]. In contrast, we have found that atropine did not
abolish the effect of VNS on the VF inducibility in the
isolated innervated rabbit heart [103]. This may reflect
differences in the methodology of VF induction or species
differences in muscarinic receptor distribution, but more
importantly the existence of different cellular mechanisms.
Since the discovery of a functional M3 mAChR in the
mammalian myocardium by Jaiswal et al. [105], there have
been significant advances in our understanding of the roles
of M3 in the control of cardiovascular physiology. The
Gq-protein linked M3 mAChR is known to modulate heart
rate and cardiac repolarisation, regulate cell-to-cell com-
munication, be beneficial against ischaemic and oxidative
injury, and promote or suppress the formation of arrhyth-
mias in a manner dependent on the location of and/or
phenotype of arrhythmia, that is, atrial (increased) versus
ventricular (decreased) [106]. Pharmacological activation
of M3 receptors reduces the occurrence of ischaemia-,
aconitine- and ouabain-induced ventricular arrhythmias
[107]. Further to this, over-expression of the M3 mAChR
gene reduces the occurrence of spontaneous arrhythmias in
a mouse model of ischaemia reperfusion [108]. The role of
the M3 receptor in regulating cardiac repolarisation and
cell-to-cell communication is particularly relevant to the
discussion of ventricular arrhythmia susceptibility. The M3
receptor activation can stimulate the potassium channel
IKM3 [109], which has been shown to directly modulate
cardiac membrane repolarisation [110]. Studies in isolated
cells suggest that M3 activation reduces calcium overload
in ventricular myocytes, and it has been proposed that this
action mediates its protective action in ischaemia-induced
arrhythmias [110]. In addition, the M3 receptor appears to
regulate the expression of phosphorylated connexin-43
(Cx43), a gap junction channel protein highly expressed
in ventricular tissue and reduced in ischaemia and HF.
Efferent vagal nerve stimulation may protect the heart form
ischaemia-induced arrhythmias by preventing a reduction
of phosphorylated Cx43 associated with ischaemia [111].
Similarly chronic therapy with VNS appears to normalise
the expression of Cx43 within the left ventricular myo-
cardium of dogs with HF [83].
Evidence from studies in gene knockout mice suggests
that the effects of M3 activation oppose those of the M2
receptor, to enhance contractility and increase heart rate
[45]. It is recognised that the M3 receptor promotes
arrhythmias in atrial tissues but suppresses ventricular
arrhythmias (a likely result of opposing effects on repo-
larisation time course), which may indicate difference in
the distribution of the mAChRs throughout the myocar-
dium or regional variations in ion channel expression (e.g.
greater IKACh in atrial tissues). Importantly, the expression
of M3 appears to be increased in hearts from patients with
congestive heart failure [106]. Whilst pharmacological
evidence supports the anti-arrhythmic role of the M3
receptor, its contributions to the action of the vagus nerve
remain to be elucidated.
Heart rate reduction and ventricular refractoriness
An obvious consideration when stimulating the vagus
nerve is the resulting bradycardia. Some studies suggest
that the anti-arrhythmic influence of the vagus nerve is
reduced but not abolished when the heart rate is controlled
[51, 52, 56, 58]. We have shown that the anti-VF effect of
VNS is preserved during constant pacing in the isolated
innervated rabbit heart [38]. In addition, we have shown
that despite differential heart rate effects of left and right
VNS, the anti-fibrillatory effect is equipotent [38]. The
mechanisms by which a reduction in heart rate could pro-
tect from ventricular arrhythmias is not understood, but
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may include rate-dependent alterations in ventricular APD,
refractoriness and dispersion of both factors. It is widely
recognised that VNS prolongs ventricular APD and ERP
[38, 104, 112, 131]. The direction of change in ERP during
autonomic nerve stimulation mimics the change in VFT
[38]. Using optical mapping of ventricular APD, we have
shown that bilateral VNS reverses the sequence of ven-
tricular repolarisation [113] although it is not clear how this
might be cardioprotective. Detailed study on the effects of
VNS on ventricular repolarisation is clearly needed. A
similar anti-fibrillatory action has been noted when porcine
hearts are treated with Ivabradine, an inhibitor of the
pacemaker current (If), [114] though it is not clear whether
this is a consequence of induced bradycardia or from non-
specific effects on other ion channels [115].
A common finding of clinical trials on HF is a negative
correlation between heart rate and patient survival and the
ability to increase heart rate in response to exercise [116].
The relationship between heart rate and mortality holds
true in untreated patients and in those receiving b-blockers,
although a reduction in heart rate and risk is seen in the
latter. High heart rate is associated with cardiovascular risk
by a number of independent factors (e.g. increased ven-
tricular wall stress, decreased arrhythmic threshold) and
factors which are related to adrenergic hyperactivity (i.e.
left ventricular hypertrophy, lower arrhythmic threshold)
[116]. VNS provides a mechanism, in addition to
b-blockade, to reduce heart rate in these high risk patients;
however, a large reduction in heart rate may not be ideal as
excessive bradycardia carries its own potential risk. As
with other studies, it is difficult to assess the relative
contribution of different factors (i.e. heart rate reduction
and direct electrophysiological effects) to the overall risk
of higher heart rates, especially in regards to b-blockade
and VNS with their multiple sites of action.
The relative importance of bradycardia as a protective
mechanism is unclear and contrasts with our findings that
the effects of VNS are preserved during constant ventric-
ular pacing. VNS still has a profound effect on ventricular
electrophysiology during constant pacing, reducing sus-
ceptibility to VF [38]. Studies conducted in 1952 by Silvo
Weidmann [117] first demonstrated the role of time course
of repolarisation in the excitability of Purkinje fibre and
demonstrated that the membrane potential needed to return
to at least -55 mV, following a triggered action potential,
before another action potential could be elicited [117]. The
electrophysiological implication of this is that factors (i.e.
pharmacological, physiological) which shorten the time
course of repolarisation are likely to be arrhythmogenic.
Studies using anoxia and acetylcholine, the latter in atrial
tissue, support this conclusion, accelerating repolarisation
and promoting arrhythmia generation [118]. Increases in
ERP, occurring without significant changes in conduction
velocity, may provide protection from re-entrant arrhyth-
mias although this may only be true if APD prolongation is
uniform across the ventricular surface, as appears to be the
case during VNS in the dog [112] but not in our studies in
the innervated rabbit heart [113]. Several class III anti-
arrhythmic compounds, such as amiodarone and sotalol,
prolong phase 3 of the cardiac action potential and are
recognised to reduce the occurrence of atrial and ventric-
ular arrhythmias [119], although these compounds affect
several different aspects of cardiac electrophysiology.
Another important concept in the generation of ven-
tricular arrhythmias is that of action potential duration
dispersion. Spatial repolarisation heterogeneity provides a
substrate for the generation of ventricular arrhythmias, and
dispersion of APD is a known mechanism underlying cir-
cus movement re-entry around refractory regions [120].
Although previous investigators have noted that the effects
of VNS on electrophysiology are uniformly distributed
[112], with no effects of APD dispersion, it is known that
the SNS promotes a greater degree of APD shortening in
basal regions of the ventricle [121], data which are sup-
ported by histological studies of sympathetic nerve distri-
bution [122, 123]. When there is a background sympathetic
tone, VNS may prevent arrhythmias by antagonising
sympathetic mediated changes in spatial repolarisation (see
accentuated antagonism). This idea may be particularly
relevant in HF where there is an increased activation and
influence of the sympathetic nervous system.
Nitric oxide
The biosynthesis and multitude of biological functions of
nitric oxide (NO) have been reviewed extensively else-
where [123–127]. Our discussion will focus on the role of
NO in relation to the parasympathetic nervous system.
Direct NO-dependent effects on arrhythmia susceptibility
It is widely accepted that NO is involved in both central
and peripheral aspects of vagal control, not only in terms of
cardiac function but also in other bodily systems such as
the GI tract [128]. In the heart, NO appears to modulate the
actions of the parasympathetic nervous system, regulating
the change in HR in response to parasympathetic stimula-
tion [129]. Herring et al. [130] suggested that NO acts pre-
synaptically to reduce the bradycardic response to VNS.
Other investigators have noted that NO modulates changes
in A-V conduction in response to VNS in a similar manner
[129] and suggests that NO has a role in the ventricular
effects of VNS. We directly tested this possibility using the
innervated rabbit heart.
After confirming the anti-VF effect of VNS together
with an increase in ERP and reduction in the slope of the
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restitution curve, we perfused the innervated heart prepa-
ration with the non-specific nitric oxide synthase (NOS)
inhibitor L-NA and investigated the effects of VNS. In the
presence of L-NA, the increase in VFT and flattening of
electrical restitution slope with VNS were abolished whilst
the increase in ERP was preserved [131] (see Fig. 3). The
response to VNS was restored by supplementation with L-
Arginine, the NO substrate which competes with L-NA for
binding to NOS. This anti-arrhythmic effect of NO is
supported by the work of Kumar et al. [132], who dem-
onstrated that exogenous intrapericardially applied nitro-
glycerine significantly reduced the occurrence of
ischaemia-induced VF. We later showed that NO donor,
sodium nitroprusside, increased VFT, ERP and reduced the
slope of the restitution curve in a similar manner to VNS
[133]. These data tentatively show that (1) electrical res-
titution is important as a mechanism during VNS protec-
tion from VF as the effects of restitution and VFT parallel
one another, (2) vagally mediated changes in perfusion
pressure, heart rate and ERP do not appear to be signifi-
cantly involved in vagal protection against VF as the
changes are disproportionate in comparison with the
changes in VFT and restitution, and (3) NO plays a key role
in this protective effect.
Although the aforementioned study provides basis for a
working hypothesis for NO in mediating the ventricular
effects of the vagus, it provided only indirect evidence of
this mechanism. Through the use of the NO-sensitive dye
DAF-2 DA, we were able to provide direct evidence of
VNS-mediated NO release [134]. NO-dependent fluores-
cence was found to increase during both left and right
cervical VNS in relation to the intensity of stimulation (see
Fig. 4). Perfusion of L-NA significantly decreased back-
ground fluorescence, indicative of a reduction in basal NO
production (presumably from the endothelium), and abol-
ished the increase in fluorescence seen with VNS. TRIM, a
specific antagonist of the neuronal form of NOS (nNOS or
NOS I), had no effect on background fluorescence but
abolished the fluorescence increase with VNS supporting
the notion that NO production during VNS occurs through
nNOS.
More recently, we have extended these findings to show
that these effects of the vagus do not occur through acti-
vation of mAChR’s since perfusion with atropine at a
concentration sufficient to block changes in heart rate and
ERP did not influence the vagal effect on DAF-2 fluores-
cence, the reduction of the slope of the electrical restitution
curve or increase in VFT [104]. In addition, this study
indicates that the protective effects do not involve the
endothelium (a substantial source of NO in the heart) as
effects are preserved after functional endothelial denudation
or during inhibition of vasoactive intestinal peptide (VIP)
which is a neuroactive peptide released together with ACh.
It has previously been suggested that vagally released
ACh and NO can act through parallel independent signal-
ling pathways [135]. Given our evidence that NO produc-
tion during VNS occurs through nNOS independent of the
endothelium, VIP or ACh, we tentatively propose the
existence of a separate network of parasympathetic–
nitrergic anti-fibrillatory neurones [136] within the ventricle.
It is known that nNOS is present in many parasympathetic
neurones innervating the heart [137, 138], and there is also
evidence of a subpopulation of intracardiac nerve fibres
that contain solely NO coursing towards the ventricle in
humans, providing supportive evidence for our hypothesis
[139]. Given recent demonstrations of significant popula-
tions of parasympathetic innervation in the ventricles of
mammalian species, refuting the classical view of sparse
innervation, detailed neuro-anatomical information on the
chemical phenotype of parasympathetic nerves within the
ventricle is warranted.
VNS, NOS expression and NO signalling
NOS expression is found in endothelial cells, myocytes and
neuronal cells, and it regulates a huge range of biological
functions in a manner which appears to be dependent upon
location [124–127]. The relative expression of the different
NOS isoforms is altered significantly in both experimental
and human HF, and dysfunction of NO signalling may be
causally associated with many pathological changes associ-
ated with HF (i.e. reduced contractile function). Importantly
studies conducted in dogs with microembolism-induced HF
demonstrate that chronic VNS normalises both mRNA and
gene expression of NOS [83]. Information on how alterations
of NOS expression may alter ventricular arrhythmia suscep-
tibility is currently lacking. Moreover, studies on the role on
the NO-dependent anti-fibrillatory effects of VNS have not
been carried out in failing hearts. Further studies are required
to address the role of alterations in NO signalling and NOS
expression in ventricular arrhythmia susceptibility and how
VNS may modulate these mechanisms.
Role of intracardiac neuronal networks and afferent
nerve activation
It is recognised that direct neurochemical stimulation of
decentralised intrinsic cardiac neurones can generate atrial
and ventricular arrhythmias [42] and that the attenuation of
parasympathetic control in HF may in part relate to chan-
ges in ganglionic function, as demonstrated in dogs with
pacing induced HF [43]. Whether VNS can reverse these
changes or modulate the intrinsic neuronal network to
modify arrhythmia susceptibility is unknown.
Sensory (or afferent) nerve fibres relay information
from the myocardium to the brain for processing, and
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approximately 70 and 80 % of the vagus nerve consists of
these afferent fibres. Therefore, electrical stimulation of the
vagus may capture both afferent and the effector efferent
nerves, unless selective stimulation protocols, such as
anodal block, are used to exclude a specific population of
neurones. The contribution of these distinct populations of
nerves to the anti-arrhythmic benefits of VNS is currently
unknown. Studies conducted in our laboratory with the
innervated rabbit heart show that the protective effect of
VNS is not dependent upon the brain, but these experi-
ments do not exclude the existence of additional
anti-arrhythmic mechanisms in vivo or afferent reflex
responses which can occur locally [38]. An earlier study
rules out antidromic afferent nerve stimulation as a
potential mechanism, since the response is lost during
perfusion of the ganglionic transmission inhibitor hexa-
methonium. Myers et al. [52] demonstrated that the pro-
tective effects of VNS were maintained following
decentralisation of the vagus nerve, but quantitative com-
parison of responses between groups was not carried out.
Afferent nerve activation provides a, speculative, ‘expla-
nation’ of the beneficial effects of chronic low-intensity
Fig. 3 A direct nitric oxide synthase(NOS)–dependent anti-arrhyth-
mic influence of vagus nerve stimulation. NOS-dependent anti-
arrhythmic influence of vagus nerve stimulation (VNS) in the isolated
innervated rabbit heart. a and b Data from a single experiment
demonstrating how the influence of VNS on the restitution slope is
abolished by perfusion with L-NA and restored by L-arginine (L-Arg).
c, d and e Mean data effects of L-NA and L-NA ? L-Arg on VNS
induced changes in restitution slope, effective refractory period (ERP)
and ventricular fibrillation threshold (VFT), respectively. *P \ 0.05;
comparison to baseline or between groups. Reproduced with permis-
sion from Brack et al. [104]
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VNS on haemodynamic parameters and remodelling in
experimental HF (i.e. where no change of cardiac rate is
seen) [84]. Afferent nerve activation and the modulation of
central processes controlling autonomic outflow is a dis-
tinct possibility which requires attention.
Role of vagal activated anti-inflammatory pathways
Another mechanism by which the parasympathetic nervous
system may protect the heart is via an anti-inflammatory
action. It has become increasingly evident over the two
decades that inflammatory responses can be modulated and
feedback into the autonomic nervous system, the so-called
inflammatory reflex [140]. Locally released cytokines can
activate sensory fibres which relay information to the
central nervous system influencing efferent signals (refs).
Vagotomy has a pronounced effect on the cytokine
response to injury and ACh, acting through nicotinic ACh
receptors, can inhibit the release of several cytokines [141].
The intracellular signalling pathways mediating this
response have been reviewed by Li and Olshansky [142].
Interestingly, a strong inverse correlation between HRV
and levels of inflammatory cytokines was report in a trial
examining coronary artery risk in young adults [143].
Lower levels of cytokines are associated with a restricted
inflammatory response in following MI and in HF, where it
is recognised that arrhythmias contribute to a significant
proportion of deaths.
The role of inflammation in the generation of arrhyth-
mias in HF and following ischaemic injury is not clear, but
it is recognised that malignant arrhythmias are more likely
in patients with acute and chronic myocarditis [144, 145].
Cytokines can exert a direct action on myocyte electro-
physiology but can also indirectly increase the suscepti-
bility of the heart to arrhythmias by promoting the
formation of non-conductive scar and fibrotic tissue,
hypertrophy and atrophy of myocytes and impairment of
oxygen availability [146]. Mice engineered to over-express
tumour necrosis factor-a have been commonly used as a
model of congestive HF, exhibiting a large number of ion
channel conductance abnormalities and increased suscep-
tibility to induced arrhythmias compared to wild-type
controls [147–149]. Animals with TNF-a-induced failure
exhibit a number of different types of arrhythmia, included
atrial tachycardia, AF, non-sustained VT and ventricular
ectopy, have altered repolarisation characteristics and
dysregulated intracellular calcium homoeostasis [147].
Further study is warranted into the role of cytokines in
arrhythmias and the potential role of the vagus in modu-
lating this process. More detailed information on how
Fig. 4 Direct measurement of
NO release during vagus nerve
stimulation. Measurement of
nitric oxide release during
cervical vagal nerve stimulation
(VS), using the fluorescent
indicator DAF2-DA, in the
isolated innervated rabbit heart.
a Raw data from a single
experiment illustrating the
change in left ventricular
pressure (LVP), aortic perfusion
pressure (AP) and nitric oxide
dependent florescence (F490)
during low-, medium- and high-
intensity VS. b and c Mean data
demonstrating the change in
F490 before, during and after
individual left and right VS.
*P \ 0.05, **P \ 0.01,




permission from Brack et al.
[134]
Heart Fail Rev (2013) 18:389–408 403
123
inflammatory pathways may modulate ventricular electro-
physiology is required and represents an area of some
interest. It is possible that these studies could provide novel
targets for the treatment for ventricular arrhythmias in HF
and other arrhythmogenic conditions (i.e. long QT syn-
drome). It is recognised that inflammatory pathways may
play an important role in the remodelling of the ventricles
in HF [146] and that VNS can prevent/normalise ventric-
ular phenotype in conjunction with the suppression of
inflammatory activation. The structural abnormalities
associated with ventricular remodelling (i.e. fibrosis and
hypertrophy) may contribute to increased arrhythmic risk,
and it is likely that VNS-mediated suppression of these
pathways is a contributing factor to the anti-arrhythmic
action of chronic VNS therapy in HF. This idea differs
from the direct role of inflammatory mediators in
arrhythmia susceptibility.
Conclusions
The profound anti-arrhythmic influence of the vagus nerve
has provided modern clinical practice with valuable tools
for assessing risk in the form of HRV and BRS, and
chronic VNS may prove to be a powerful therapy for heart
failure. The effects of the vagus nerve on ventricular ar-
rhythmogenesis are multi-faceted involving effects on
heart rate, interactions with the sympathetic nervous sys-
tem, anti-inflammatory influences and a direct effect on
ventricular electrophysiology. Our data indicate that the
vagus nerve exerts a direct anti-arrhythmic action at the
level of the ventricles through the release of NO—a ten-
tative-independent nitrergic neural network regulating
cardiac physiology which could potentially offer a novel
therapeutic avenue.
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